ArticleMolecular biology reports2026
Papain induces Mitochondria-mediated apoptosis and modulates inflammatory signaling in leukemic cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeukemia remains a major therapeutic challenge due to frequent treatment resistance and relapse. Novel agents that preferentially target leukemic cells are urgently needed. Papain, a cysteine protease derived from Carica papaya, has been reported to exhibit antioxidant, anti-inflammatory, and anticancer properties; however, its molecular effects in leukemia cells remain poorly understood.
objectivesThis study aimed to evaluate the antileukemic effects of papain on HL-60 and K562 cells, focusing on apoptosis induction, cell-cycle regulation, inflammatory modulation, and gene/protein expression changes.
methodsHL-60 and K562 cells were treated with papain at 123 µM and 386-483 µM, respectively, for 24-48 h. Concentrations were selected based on IC₂₅ values for HL-60 and IC₅₀ values for K562 obtained from viability assays. Cell viability was assessed using the MTS assay. Apoptosis, cell-cycle distribution, and surface expression of **Sema3A-a semaphorin family member involved in immune regulation and leukemic cell signaling-**were analyzed using flow cytometry. RT-qPCR quantified expression of apoptosis-related genes (P53, PTEN, BAX, CASP3, BCL-2, AKT-1, NF-κB), and ELISA measured Cytochrome c, Cleaved Caspase-3, TNF-α, IL-6, IL-10, GPX4, and ACSL4.
resultsPapain significantly reduced cell viability in both cell lines in a dose- and time-dependent manner. Increased Cytochrome c and Cleaved Caspase-3 levels suggested apoptosis induction. Papain exposure led to predominant accumulation of cells in the G₀/G₁ phase accompanied by a reduction in the G₂/M population in HL-60 cells, whereas in K562 cells it induced a significant and dose-dependent accumulation in the S phase rather than G₂/M arrest. Papain induced significant alterations in apoptosis-related gene expression in both leukemia cell lines. These changes reflected activation of apoptotic signaling pathways rather than a uniform dose-dependent or directionally consistent transcriptional pattern. Furthermore, papain significantly downregulated Sema3A surface expression and altered cytokine profiles, increasing TNF-α and IL-10 in both cell lines and IL-6 in K562 cells.
conclusionPapain exhibits antileukemic effects in vitro, associated with mitochondrial-mediated apoptosis, altering cell-cycle progression, suppressing Sema3A expression, and modulating inflammatory responses. These findings suggest that papain may represent a candidate for further preclinical investigation in leukemia models.
Indexed as
Identifiers
41604059What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.